Research that Identifies
Undiscovered Value in the MicroCap Market

Nephros, Inc.

Nephros, Inc. Email List: Click to Subscribe

View Company Website: Click to View

Market Data: Yahoo Finance, Bloomberg, SEC

Report Link: Updated Research Report (Dated 05/14/2019)

Symbol: NEPH
Analyst: Howard Halpern
Taglich Rating: Speculative Buy
Price Target: $9.00
Time Horizon: 12 Months
Rating Established: April 24, 2019
Price When Established: $4.50
Most Recent Report: May 14, 2019
Price When Issued: $0.58

What's New

Nephros Announces Preliminary 2Q19 Sales and a Reverse Stock Split

On July 9, 2019, Nephros, Inc. announced preliminary 2Q19 sales for the three-months ended June 30, 2019.

Nephros expects to report total sales of approximately $2.3 million or nearly a 70% increase from 2Q18. The company is maintaining its 2019 full year sales guidance of $8.5 million to $9.5 million.

We project 2Q19 and 2019 sales of $1.9 million and $8.8 million, respectively.

As part of the company’s plan to uplist its common stock to a national stock exchange, Nephros effected a 1-for-9 reverse stock split effective July 10, 2019. The company’s share will trade on the OTCQB exchange under the symbol NEPHD for 20 trading days after which its symbol will return to NEPH.

The split-adjusted price based on the July 9, 2019 closing price (of $0.62) is $5.58 per share.

Company Description

Nephros Inc., headquartered in South Orange, New Jersey, is a water purification company that develops and sells high performance filters and ultrafilters (filters with pore size below 0.01 microns) primarily to hospitals for the prevention of infection from waterborne pathogens and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrates. An acquisition in December 2018 expanded NEPH’s commercial market footprint to include the food service and hospitality industries. The company’s 62.5% owned subsidiary, Specialty Renal Products is a development stage company focused on improving therapies for patients with renal disease.

Company Reports

Updated Research Report (Dated 05/14/2019)

Initial Research Report (Dated 04/24/2019)


Please view our current disclosure and disclaimer on our most recent research report.